Journals / Turkish Journal of Medical Sciences / 2020 / Cilt: 50 - Sayı: 1

Total oxidant and antioxidant status and paraoxonase 1 levels of children with noncystic fibrosis bronchiectasis

Pages
1–7
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The patients with low FEV1 had decreasedTAC when compared to those who had normal FEV1 in non-CF BE.Conclusion: The present study demonstrated that compared with the control group the children with non-CF BE had elevated oxidativestatus, antioxidant defenses parameters, and PON1 values.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: To evaluate total oxidant status (TOS), total antioxidant capacity (TAC), and paraoxonase 1 (PON1) levels in childrenwith noncystic fibrosis (CF) bronchiectasis (BE), and to compare these levels with those of healthy controls.
📊
Key Findings & Data:The study parameters werealso evaluated according to some demographic, anthropometric, and clinical characteristics, as well as lung functions.Materials and methods: Enrolled in the study were 118 children with non-CF BE and 68 healthy controls.
💡
Conclusion & Impact:The patients with low FEV1 had decreasedTAC when compared to those who had normal FEV1 in non-CF BE.Conclusion: The present study demonstrated that compared with the control group the children with non-CF BE had elevated oxidativestatus, antioxidant defenses parameters, and PON1 values.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: To evaluate total oxidant status (TOS), total antioxidant capacity (TAC), and paraoxonase 1 (PON1) levels in childrenwith noncystic fibrosis (CF) bronchiectasis (BE), and to compare these levels with those of healthy controls. The study parameters werealso evaluated according to some demographic, anthropometric, and clinical characteristics, as well as lung functions.Materials and methods: Enrolled in the study were 118 children with non-CF BE and 68 healthy controls. Serum TOS, TAC, and PON1levels were determined. Lung function tests were performed by spirometry.Results: Serum TOS was higher in the patients [median 9.54 (IQR 25–75 = 7.05–13.30) μmol H2O2 Eq/L] than in the healthy subjects[6.64 (5.45–9.53) μmol H2O2 Eq/L] (P < 0.001). TAC was higher in patients with non-CF BE [1.07 (1.0–1.07) mmol Trolox Eq/L] thanin the healthy controls [0.87 (0.77–0.98) mmol Trolox Eq/L] (P < 0.001). In addition, serum PON1 levels were significantly higher inthe patients [106.5 (42.5–154.2) U/L] than in the controls [47.7 (27.5–82.1) U/L] (P < 0.001). The patients with low FEV1 had decreasedTAC when compared to those who had normal FEV1 in non-CF BE.Conclusion: The present study demonstrated that compared with the control group the children with non-CF BE had elevated oxidativestatus, antioxidant defenses parameters, and PON1 values.

🔖

Cite This Article

TÜRKMEN, A. V., ÖZER, Ö. F., KAYGUSUZ, S. B., GEDİK, A. H., ÇAKIR, E. (2022). Total oxidant and antioxidant status and paraoxonase 1 levels of children with noncystic fibrosis bronchiectasis. Turkish Journal of Medical Sciences, Cilt: 50 - Sayı: 1, 1–7. https://ajindex.com/articles/609651

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society Guideline for non-CF bronchiectasis. Thorax 2010; 65: 1-58
  2. Bergin DA, Hurley K, Mehta A, Cox S, Ryan D, O’Neill SJ, Reeves EP, McElvaney NG. Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis. J Inflamm Res 2013; 6: 1-11
  3. MacNee W. Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol 2001; 429: 195-207
  4. Tzortzaki EG, Dimakou K, Neofytou E, Tsikritsaki K, Samara K, Avgousti M, Amargianitakis V, Gousiou A, Menikou S, Siafakas NM. Oxidative DNA damage and somatic mutations: a link to the molecular pathogenesis of chronic inflammatory airway diseases. Chest 2012; 141: 1243-1250
  5. Heunks LMA, Dekhuijzen PN. Respiratory muscle function and free radicals: from cell to COPD. Thorax 2000; 55: 704-716
  6. Litvinov D, Mahini H, Garelnabi M. Antioxidant and anti-inflammatory role of paraoxonase 1: antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. N Am J Med Sci 2012; 4: 523-532
  7. Mackness M, Mackness B. Targeting paraoxonase-1 in atherosclerosis. Expert Opin Ther Targets 2013; 17: 829-837
  8. Nadeem A, Chhabra SK, Masood A, Raj HG. Increased oxidative stress and altered levels of antioxidants in asthma. J Allergy Clin Immunol 2003; 111: 72-78
  9. Soler N, García-Heredia A, Marsillach J, Mackness B, Mackness M, Joven J, Romero P, Camps J. Paraoxonase-1 is associated with corneal endothelial cell alterations in patients with chronic obstructive pulmonary disease. Invest Ophthalmol Vis Sci 2013; 54: 5852-5858
  10. Back EI, Frindt C, Nohr D, Frank J, Ziebach R, Stern M, Ranke M, Biesalski HK. Antioxidant deficiency in cystic fibrosis: when is the right time to take action? Am J Clin Nutr 2004; 80: 374-384
  11. Lezo A, Biasi F, Massarenti P, Calabrese R, Poli G, Santini B, Bignamini E. Oxidative stress in stable cystic fibrosis patients: do we need higher antioxidant plasma levels? J Cyst Fibros 2013; 12: 35-41
  12. Fuschillo S, De Felice A, Balzano G. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J 2008; 31: 396-406
  13. Tarpey MM, Wink DA, Grisham MB. Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations. Am J Physiol, Reg Integr Comp Physiol 2004; 286: 431-444
  14. Erel O. A new automated colorimetric method for m